Acadia signs licensing deal for essential tremor drug candidate

Acadia Pharmaceuticals (NASDAQ:ACAD) has entered into an exclusive global licensing deal with Danish drug developer Saniona to develop and commercialize Saniona’s drug candidate SAN711 for the treatment of essential tremor.

Under the deal, Saniona will receive $28M upfront plus up to $582M in